Although we have only investigated the anti-lung cancer activity of 9za in vitro until now, we can anticipate the potent anti-tumor effect in vivo based on that 9za is a dual MEK/PDK1 inhibitor and has stronger anti-cancer efficacy than the single MEK/PDK1 inhibitor. This evidence concerns the gene MAP2K7 and lung cancer.